Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nkarta, Inc. filings document the regulatory record of a clinical-stage biotechnology company advancing engineered NK cell therapies for autoimmune disease. Recent 8-K reports disclose quarterly and annual financial results, corporate highlights, and clinical-program references for NKX019 and the Ntrust studies.
The company’s proxy materials cover annual meeting governance, director elections, auditor ratification, executive compensation votes, and stockholder voting mechanics. Other filings describe capital-raising infrastructure, including a Form S-3 registration statement and an at-the-market sales agreement for common stock, as well as emerging growth company reporting status and related Exchange Act disclosures.
Nkarta, Inc. filed a shelf registration on Form S-3 to register up to $350,000,000 of securities, including an at-the-market program for up to $100,000,000.
The shelf prospectus describes offers of common stock, preferred stock, debt securities, warrants, rights and units that may be sold separately or together in one or more offerings. The at-the-market sales agreement with Stifel, Nicolaus & Company, Incorporated permits sales of up to $100,000,000 of common stock under an ATM; Stifel may act as agent or principal and may receive up to 3.0% of gross proceeds as compensation. The prospectus discloses 74,290,521 shares of common stock issued and outstanding as of March 18, 2026 (including 3,000,031 shares underlying pre-funded warrants) and notes that specific terms for each offering will be provided in prospectus supplements.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off‑the‑shelf engineered NK cell therapies, led by NKX019, a CD19‑targeted CAR NK candidate for B‑cell–mediated autoimmune diseases such as lupus nephritis, primary membranous nephropathy, scleroderma, myositis and ANCA‑associated vasculitis.
NKX019 is in multiple Phase 1 trials (Ntrust‑1, Ntrust‑2) and investigator‑sponsored studies, supported by an internal CAR NK platform, cGMP manufacturing in South San Francisco and an extensive patent estate. The company has no approved products, has incurred significant losses and expects to need additional capital. As of June 30, 2025, equity held by non‑affiliates was valued at approximately $82.6 million, and as of March 18, 2026, there were 71,290,490 common shares outstanding.
Nkarta, Inc. reported fourth quarter and full year 2025 results and highlighted progress in its NKX019 autoimmune program. Cash, cash equivalents, restricted cash and investments totaled $295.1 million as of December 31, 2025, and are expected to fund operations into 2029.
For 2025, Nkarta recorded a net loss of $104.1 million, or $1.41 per share$90.4 million and general and administrative expenses were $31.6 million. Fourth quarter 2025 net loss was $27.4 million, or $0.37 per share.
Clinically, dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7, for a total of 12 billion cells per cycle in the Ntrust-1 and Ntrust-2 autoimmune trials. Initial clinical data from these trials are planned for presentation at a medical conference in 2026.
Tang Capital Management and related entities filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership in Nkarta, Inc. common stock. They report beneficial ownership of 1,480,823 shares, representing 2.1% of Nkarta’s common stock, based on 71,029,512 shares outstanding as of November 5, 2025. The shares are held with no sole voting or dispositive power and with shared voting and dispositive power over 1,480,823 shares across Tang Capital Management, Tang Capital Partners, Tang Capital Partners International and Kevin Tang. The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of Nkarta, indicating a passive investment stance and confirming ownership of 5% or less of the class.
Nkarta, Inc. insider transaction: Chief Executive Officer and director Paul J. Hastings reported an automatic sale of 26,046 shares of Nkarta common stock on 01/15/2026 at a price of $2.07 per share. The filing explains that these shares were sold to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units and that the transaction was not a discretionary trade by the reporting person. Following this tax-related sale, Hastings beneficially owned 390,023 shares of Nkarta common stock directly.
Nkarta, Inc. (NKTX) president Mahmood Nadir reported a small sale of company stock related to tax withholding. On January 15, 2026, he sold 5,649 shares of Common Stock at $2.07 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, and were not a discretionary sale. After this transaction, he directly beneficially owned 167,727 shares of Nkarta common stock.
Nkarta, Inc. insider Rose Shawn Marshall, the company’s Chief Medical Officer and Head of Research & Development, reported new equity awards on a Form 4. On January 6, 2026, Marshall received 70,000 shares of Common Stock in the form of Restricted Stock Units, granted at $0 per share. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU representing one share of Nkarta common stock.
On the same date, Marshall was also granted a stock option to buy 139,000 shares of Common Stock at an exercise price of $1.93 per share. This option is scheduled to vest in 48 equal monthly installments, based on continued service after January 14, 2026, and expires on January 5, 2036. Both awards are reported as directly owned following these transactions.
Nkarta, Inc. reported an equity award to its President, Mahmood Nadir, in the form of both restricted stock units and stock options. On 01/06/2026, he received 80,000 shares of Common Stock as Restricted Stock Units, which are scheduled to vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock.
On the same date, he was also granted a stock option covering 160,000 shares of Common Stock at an exercise price of $ 1.93 per share, expiring on 01/05/2036. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026, contingent on continued service. After these transactions, he directly beneficially owned 173,376 shares of Common Stock and 160,000 derivative securities.
Nkarta, Inc. reported an insider equity award for Chief Executive Officer and director Paul J. Hastings. On January 6, 2026, he received 94,000 shares of Common Stock in the form of Restricted Stock Units, granted at a price of $0. These RSUs vest in four equal annual installments beginning on January 14, 2027, with each RSU convertible into one share of Common Stock.
On the same date, Hastings was also granted a stock option for 562,000 shares of Common Stock at an exercise price of $1.93 per share, with no cost reported for the grant itself. This option is scheduled to vest in 48 equal monthly installments following January 14, 2026. After these transactions, he beneficially owned 416,069 shares of Common Stock directly, along with the 562,000 stock options. The share total includes 2,000 shares acquired under Nkarta’s 2020 Employee Stock Purchase Plan on November 30, 2025.
Nkarta, Inc. reported Q3 2025 results. Net loss was $21.7M or $0.29 per share, driven by operating expenses of $27.3M (R&D $20.2M; G&A $7.1M). Other income of $5.6M included $1.7M received for Employee Retention Credit claims, with $1.5M recognized in other income and $0.2M in interest. Year‑to‑date net loss was $76.7M.
Balance sheet and liquidity. Cash, cash equivalents, restricted cash and investments totaled $316.5M as of September 30, 2025 (cash and equivalents $60.1M, short‑term investments $222.2M, long‑term investments $31.4M). Total assets were $427.2M and stockholders’ equity $337.9M. Operating cash use year‑to‑date was $67.1M, while investing activities provided $99.2M. Management believes available funds will meet obligations for at least twelve months from the filing date. The company recorded a $0.8M impairment to right‑of‑use assets and ended with lease liabilities of $76.6M. A March workforce reduction (~34%) carried total severance of $5.4M; $0.7M remained accrued at quarter‑end. Clinically, deep B‑cell depletion was observed with Flu/Cy lymphodepletion, and the iDSMB authorized enrollment in the second dose‑escalation cohort.